Same Indication

Lutetium Lu-177 Vipivotide Tetraxetan vs Trastuzumab

Lutetium Lu-177 Vipivotide Tetraxetan vs Trastuzumab: Overview

This comparison examines the pharmacological differences between Lutetium Lu-177 Vipivotide Tetraxetan and Trastuzumab.

Mechanism of Action

Trastuzumab: Anti-HER2 monoclonal antibody inhibiting receptor signaling.

Pharmacokinetics

Half-life: Trastuzumab — 28 days.

Chemical Properties

Type: Lutetium Lu-177 Vipivotide Tetraxetan — Protein; Trastuzumab — Antibody.